Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03457597
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Relacorilant Food Effect Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Food-drug InteractionHealthy
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT03442621
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Phase 1
Completed
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT03437941
- Locations
- ๐บ๐ธ
New York, New York, New York, United States
๐ฌ๐งSouthampton, Southampton, England, United Kingdom
๐บ๐ธScottsdale, Scottsdale, Arizona, United States
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Terminated
- Conditions
- Cushing SyndromeHypercortisolism
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT03379363
- Locations
- ๐บ๐ธ
Corcept Therapeutics, Menlo Park, California, United States
CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CORT125281, 40mg, fastedDrug: Placebo oral capsule, fedDrug: CORT125281, 360mg, fastedDrug: CORT125281, 240mgDrug: Placebo oral capsule, fastedDrug: CORT125281, 120mg, fastedDrug: CORT125281, 720mg, fastedDrug: CORT125281, 360mgDrug: CORT125281, 120mgDrug: CORT125281, 180mgDrug: Placebo oral capsuleDrug: CORT125281, 360mg, fed
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT03335956
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research, London, United Kingdom
First-in-human Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CORT118335, 25 mgDrug: Placebo oral capsuleDrug: CORT118335, 75mgDrug: CORT118335, 225mgDrug: CORT118335, 675mgDrug: CORT118335, 600mgDrug: CORT118335, 375mgDrug: CORT118335, 100mgDrug: Placebo oral suspensionDrug: CORT118335, 300mgDrug: CORT118335, 900mgDrug: CORT118335, 1500mgDrug: CORT118335, 150mgDrug: CORT118335, dose to be determinedDrug: CORT118335, 630mg
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 143
- Registration Number
- NCT03315338
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT03258372
- Locations
- ๐บ๐ธ
SeaView Reserch, Miami, Florida, United States
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
Phase 1
Completed
- Conditions
- Drug Interaction PotentiationHealthy
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03259542
- Locations
- ๐บ๐ธ
SeaView Research, Miami, Florida, United States
A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-CORT125134
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT03067376
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
Completed
- Conditions
- Cushing's Syndrome
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT02922257
ยฉ Copyright 2025. All Rights Reserved by MedPath